Latest News

  • RESEARCH

    30 Jan 2026

    New Metabolic Data Reignite Interest in Liver-Targeted Lipid Drugs

  • PARTNERSHIPS

    20 Jan 2026

    Roche’s 89bio Deal Heats Up the Race for MASH Drugs

  • INSIGHTS

    19 Jan 2026

    A $160M Biotech Bet Points to Obesity Drugs’ Next Test

  • RESEARCH

    16 Jan 2026

    FDA Fast Tracks Dual-Action MASH Drug: Is Momentum Back?

Big Pharma’s Next Obesity Bet Comes in Pill Form

Lilly and Nimbus Therapeutics logos displayed to mark an obesity drug development partnership

PARTNERSHIPS

13 Jan 2026

Drugmakers push oral obesity pills into late trials, aiming to move weight loss care beyond injections and into mass-market medicine

Prolynx logo displayed in teal circle on white background

INVESTMENT

15 Dec 2025

A $70M Bet on Longer-Lasting Metabolic Drugs

Prolynx lands fresh funding and a new CEO as investors shift focus to durability and adherence in next-generation obesity therapies

Researchers reviewing biopsy data on tablet beside lab glassware and test tubes

INNOVATION

12 Dec 2025

FDA Qualifies AI Tool to Support MASH Clinical Trials

FDA qualification of an AI pathology tool could streamline MASH trials by improving consistency, hinting at broader acceptance of AI in dr...

Assorted tablets in blister packs showcasing breakthroughs in metabolic therapies.

MARKET TRENDS

11 Dec 2025

Metabolic Breakthroughs Fuel Race for Next Gen Therapies

Lilly’s data and Zealand’s Roche pact accelerate a fast-shifting field of metabolic care

Digital drug discovery interface displayed on illuminated screens at biotech research center

TECHNOLOGY

10 Dec 2025

AI Heats Up the Search for New Metabolic Treatments

AI efforts from Insilico, Nabla Bio, and Takeda speed early metabolic drug design and push firms toward faster data focused R and D

Aerial view of Novo Nordisk headquarters with circular glass roof

PARTNERSHIPS

9 Dec 2025

Metabolic Deals Speed a New US Race to Transform Liver Care

Novo Nordisk’s move for Akero boosts momentum in metabolic care; industry players should prepare for faster shifts in liver-disease treatm...

Aardvark Therapeutics logo featuring stylized A and molecular design.

INSIGHTS

8 Dec 2025

The Oral Bet Challenging Today’s GLP 1 Era

Aardvark and Rivus advance early stage metabolic therapies as interest grows beyond GLP 1 drugs and potential new options emerge

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.